Once-Weekly Semaglutide in Adults with Overweight or Obesity

This double-blind trial evaluated the efficacy and safety of once-weekly subcutaneous semaglutide (2.4 mg) combined with lifestyle intervention in 1961 adults with overweight or obesity (BMI ≥30 or ≥27 with weight-related conditions) without diabetes. Participants were randomized 2:1 to semaglutide or placebo for 68 weeks. The coprimary endpoints were percentage change in body weight and achievement of ≥5% weight loss. Semaglutide resulted in a mean weight loss of 14.9% (vs. 2.4% with placebo; estimated difference: 12.4 percentage points, P<0.001), with 86.4% achieving ≥5% weight loss (vs. 31.5% with placebo). Semaglutide also improved cardiometabolic risk factors and physical functioning. Common adverse events included transient gastrointestinal symptoms (e.g., nausea, diarrhea). The study demonstrates that semaglutide plus lifestyle intervention induces significant, sustained weight loss in adults with overweight or obesity.

This double-blind trial evaluated the efficacy and safety of once-weekly subcutaneous semaglutide (2.4 mg) combined with lifestyle intervention in 1961 adults with overweight or obesity (BMI ≥30 or ≥27 with weight-related conditions) without diabetes. Participants were randomized 2:1 to semaglutide or placebo for 68 weeks. The coprimary endpoints were percentage change in body weight and achievement of ≥5% weight loss. Semaglutide resulted in a mean weight loss of 14.9% (vs. 2.4% with placebo; estimated difference: 12.4 percentage points, P<0.001), with 86.4% achieving ≥5% weight loss (vs. 31.5% with placebo). Semaglutide also improved cardiometabolic risk factors and physical functioning. Common adverse events included transient gastrointestinal symptoms (e.g., nausea, diarrhea). The study demonstrates that semaglutide plus lifestyle intervention induces significant, sustained weight loss in adults with overweight or obesity.